Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI scans could predict lung trouble in scleroderma patients

NCT ID NCT06472362

Knowledge-focused Sponsor: Royal Brompton & Harefield NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether artificial intelligence can analyze CT scans of the lungs to predict how systemic sclerosis (a rare autoimmune disease) will affect the lungs over time. Researchers will review past scans and health records of 1,000 patients to see if certain imaging features can forecast lung scarring, blood vessel problems, and survival. The goal is to find better ways to identify high-risk patients early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which patients with systemic sclerosis will develop severe lung disease, enabling earlier and more personalized treatment.
What could go wrong
This is an observational study using historical data, so it cannot prove cause and effect. The results may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Secondary/tertiary care patients with SSc

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosed with SSc * ≥18 years old * HRCT between 01/01/1990 and 31/12/2019 Exclusion Criteria: * Patients who do not have SSc * \<18 years old * lack of availability of HRCT imaging data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bichat-Claude Bernard hospital

    Paris, France

  • Hanover Medical School

    Hanover, Germany

  • Leeds Hospital/University of Leeds

    Leeds, United Kingdom

  • Marche Polytechnic University

    Ancona, Italy

  • Royal Brompton Hospital

    London, United Kingdom

  • Sassari University

    Sassari, Italy

  • Siena University Hospital

    Siena, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.